Verge uses artificial intelligence and human data to develop better drugs faster. Verge has an end-to-end technology-driven drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets from human tissue. Verge uses machine learning to mine this data and develops these insights into new drugs using it’s human-centric biology and chemistry platforms.
First multi-modal biological foundation model for precision neurology, trained on proprietary patient data to reason about neurological disease at the patient level and generate...
AI operating system for neuroscience drug development, powered by Verge's foundation model, covering novel target discovery, program enablement, and clinical trial optimization.
Security and compliance
As reported by Verge Labs. Ask for audit reports before you buy.
administrative_safeguards
physical_safeguards
technical_safeguards
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Verge Labs Launches vBx-1.0 Foundation Model for Precision Neurology
Verge Labs introduced vBx-1.0, a foundation model designed for precision neurology. The model is trained on proprietary brain transcriptome and clinical data to reconstruct the molecular state of a patient's brain from blood samples. It is intended to help predict disease progression and treatment response, aimed at improving clinical trial efficacy. The model is currently available for preview via the company's CONVERGE platform, with ongoing efforts to validate performance on clinical trial datasets from drug development partners.
